The efficacy of alfa-interferon (alfa-IFN) in essential thrombocythemia (ET) patients has been reported by several authors. The aim of this study is to assess the magnitude of the effect of alfa-IFN on the neoplastic clone. As of December 1993, 11 ET patients received alfa-IFN at a dose of 3-6 MU/s.c./day for 6 months. Ten of 11 obtained complete hematological remission (CHR) and one achieved partial hematological remission. Megakaryocyte concentration was reduced in six cases. The spleen,which was enlarged in four patients, decreased in size in two patients. Seven of eight patients who were symptomatic at diagnosis obtained resolution of symptoms. In order to obtain indications about the structural modifications induced by alfa-IFN in ET megakaryocytes (Mks), Fourier-transform infra-red microspectroscopy analysis performed on 10 single Mks of each patient, was done in seven of 11 patients; the analysis showed a reduction of A 1 /A 2 ratios (A 1 integrated area of the band at 1080 cm −1 due to the nucleic acids absorption; A 2 integrated area of the band at 1540 cm −1 due to proteic components absorption) in five cases, and in three of these five patients A 1 /A 2 ratios achieved normal values. After alfa-IFN treatment we did not observe any change in the methylation pattern of DNA from the granulocyte fraction. Our results confirm the efficacy of alfa-IFN in ET patients, and the decrease of A 1 /A 2 ratios in several patients is a demonstration of the depth of the effect of alfa-IFN on the neoplastic clone. The results of clonality studies showed the persistence of clonal hematopoiesis. Whether higher alfa-IFN dose and/or more prolonged alfa-IFN therapy may allow a restoration of polyclonal hematopoiesis remains to be determined and should be explored in future clinical trials.
Introduction
Essential thrombocythemia (ET) is a clonal disorder of the myeloid stem cell characterized in the bone marrow by pathological expansion of the megakaryocytic elements, with a persistent increase in the platelet count. This chronic myeloproliferative disorder (CMD) does not present the Philadelphia chromosome or an increased red cell mass. The clinical course of patients affected by ET shows long intervals without any symptoms, but thromboembolic or hemorrhagic events can frequently occur. To date, there is no generally accepted treatment for ET, which is able to reduce the risk of thromboembolism and/or hemorrhagic events and avoid any increase in the frequency of secondary myelofibrosis and terminal blast transformation. Symptomatic patients are always treated, but it is extremely difficult to decide whether to treat asymptomatic cases. Thus, therapy ranges from none to the use of myelosuppressive drugs. The efficacy of alfa-interferon Correspondence: S Sacchi, Dipartimento di Scienze Mediche, Oncologiche e Radiologiche, Policlinico di Modena, 41100 Modena, Italy; Fax: 39 59 444549 Received 10 February 1997; accepted 8 November 1997 (alfa-IFN) in ET patients has been reported by several authors (Refs 1-10 and others, reviewed in Refs 1, 2 and 9); generally considered non-leukemogenic and non-gonadotoxic, reduces the platelet count rapidly, controls symptoms related to thrombocytosis and can reduce megakaryocytic mass and spleen size. Since chronic alfa-IFN treatment is very expensive and may produce severe side-effects, [11] [12] [13] [14] [15] [16] [17] [18] [19] this treatment is not generally accepted. The aim of this study is to assess the magnitude of the effect of alfa-IFN on the neoplastic clone; in other words, our goal is to verify whether alfa-IFN can exert not only a 'cosmetic' effect, but also a fundamental influence on this disease. Furthermore, we studied not only the clinical and laboratory parameters commonly used for the assessment of this disease, but we also studied megakaryocytes, at the single cell level, using Fourier-transform infra-red microspectroscopy (FT-IR-M) and we determined when possible the clonality of the peripheral blood cell fractions, using the X-chromosome restriction fragment length polymorphism (RFLP)-methylation method. Using this approach Claxton et al 20 and Lo Coco et al 21 have reported reconstitution of polyclonal hematopoiesis respectively in five and seven chronic myeloid leukemia (CML) patients who obtained Ph1 suppression, after alfa-IFN therapy. We report here on the results obtained after 6 months of alfa-IFN treatment in 11 female ET patients, found to have clonal hematopoiesis.
Materials and methods

Inclusion criteria
Criteria for inclusion were the following: (1) newly diagnosed ET or polycythemia vera (PV) patients; (2) rigorous diagnosis based on PVSG criteria; 22 (3) female gender; (4) age less than 45 years; (5) demonstration of clonal hematopoiesis; (6) performance status Ͼ 70% and (7) no previous or associated diseases which would prevent alfa-IFN treatment.
Patients
As of December 1993, 37 ET or PV patients (28 ET) entered the study, after giving informed consent. Although about 70% of ET patients are older than 45-50 years, our local ethics committee requested that we introduce a strict age limit for reducing alfa-IFN side-effects. This group of patients accounted for about 20% of the totalities of ET/PV patients seen by the seven hematological centers, during the 2-year period of enrollment in this study.
Peripheral blood cells were screened for heterozygosity at polymorphic X-linked loci phosphoglycerate kinase gene (PGK) and hypoxanthine phosphoribosyl transferase gene /l, we administered IFN at a dose of 3 MU daily, while for a count Ͼ450 × 10 9 /l, the dose was 6 MU daily. The patients self-administered the IFN injections on an outpatient basis. We treated any flu-like symptoms that appeared with paracetamol. During alfa-IFN treatment no other drugs with activity in ET were used. The alfa-IFN dose was not calculated according to body surface area to simplify the patient self-injection and to save alfa-IFN. However the body surface area of the 11 patients who entered the study varied from 1.52 to 1.77 and so we do not consider the differences in the dose intensity of alfa-IFN to be sizeable.
Toxicity
Side-effects were evaluated weekly during the first 2 weeks of treatment and then every 2 weeks.
Criteria for hematological response
We defined complete hematological response (CHR) as normalization of the platelet count (less than 400 × 10 9 /l) and partial hematological reponse (PHR), as the reduction of the platelet count ranging between 400 and 600 × 10 9 /l.
Evaluation
Pretreatment assessment included physical examination, urine analysis, blood counts, evaluation of liver and renal function, coagulation studies, serum iron and iron binding capacity, red cell mass, clonal hematopoiesis determination on peripheral blood cells, bone marrow aspiration and biopsy for morphology, cytogenetic analysis and FT-IR-M studies. Ecography confirmed the size of the spleen. We repeated blood counts and clinical examination every 2 weeks. Evaluation of renal and liver function was undertaken every month. We repeated bone marrow biopsy and aspiration for morphology and FT-IR-M studies at the end of the treatment.
Fourier-transform infra-red microspectroscopy
The experimental protocols used for FT-IR-M have previously been described. 23, 24 This technique represents an analytical method widely used in organic and inorganic chemistry. On the basis of the position and the intensity of some bands we can obtain information about the nature of the compounds of the sample examined. This technique, employed to analyze biological systems, has been used by us to study normal and leukemic lymphocytes and lately to study single megakaryocytes (Mk) from myeloproliferative disorders, which show spectral differences with respect to Mks from normal donors.
These spectral changes reflect differences in structure and/or composition of the various molecular components. Briefly, during bone marrow aspiration, a small amount of bone marrow was smeared as a thin layer on a support of barium fluoride (BaF 2 ) 12 mm in diameter and 2 mm thick, transparent to infra-red radiation. The sample was colored with a diluted Giemsa stain for 3 to 5 s, and vacuum-dried. A Spectra Tech Visible/IR Microscope Plan II directly assembled to an FT-IR Perkin-Elmer (Beaconsfield, UK) model 1760-X spectrophotometer was employed. The measurements were carried out using 15 × Reflachromat lenses. After microscopic investigation, we selected a single Mk. The borders of the Mk were then limited by means of a variable diaphragm, so that the IR radiation applied to the sample in the second step of the procedure would hit only the Mk. In this way the spectrum of the single Mk was obtained. For any given sample, both at diagnosis and at the subsequent control, 10 spectra on 10 distinct Mks were performed. Three hundred scans of 4 cm −1 resolution were signal averaged. The background spectrum, run on a clean cell-free micro area having the same size as the previously selected Mk, was automatically recorded in the memory of the instrument and subtracted from the Mk spectrum. The integrated areas of the bands at 1080 cm −1 (A 1 ) (1152-940 cm −1 baseline points), due to the PO 2 vibrations of the nucleic acid, and at 1540 cm −1 (A 2 ) (1590-1480 cm
baseline points), due to the N-H deformation of the proteic components, were calculated using the 'area' command for CDS 3-Program of the Perkin-Elmer model 7300 computer. The ratios A 1 /A 2 calculated for 10 Mks of each patient were averaged. The standard deviation for each case examined ranged from 0.02 to 0.09 (error Ͻ10%). These data were compared with others obtained from the same patient after 6 months of alfa-IFN treatment.
Clonal analysis of hematopoietic cells
Cell preparation:
In each case, 50 ml of heparinized peripheral blood was centrifuged on a Ficoll-Hypaque density gradient. The granulocyte and red cell fraction, was extensively treated with hypotonic saline to remove red cells. Then the mononuclear and the granulocyte fractions were washed twice with 0.9% NaCl. The cellular composition of the fractions was tested by morphological examination of MayGrü nwald-Giemsa-stained cytospin slide preparation. The mononuclear leukocyte fraction typically contained Ͼ90% lymphocytes and Ͻ5% monocytes; the polymorphonuclear fraction contained Ͼ85% granulocytes and Ͼ10% monocytes.
DNA hybridization analysis:
High-molecular weight DNA was prepared using the standard phenol-ethanol extraction after proteinase K digestion. By conventional Southern blot analysis the genomic polymorphism of the patients was determined for HPRT gene by BamHI and for PGK gene by BstXI digestion. Subsequently, the methylation status of the patients showing heterozygosis was analyzed using the methylation-sensitive HpaII restriction enzyme, as previously described, 25 following double digestion with BstXI and PstI in the analysis of the PGK polymorphism. The HPRT probe was a 1.4 kb fragment isolated from a plasmid subclone of the human clone 3. The PGK probe was an 800 base-pair EcoRI/BamHI fragment from the 5′ end of the PGK gene cloned into the BamHI/EcoRI sites of pSP64.
Statistical analysis
Statistical calculations were performed using the analysis of variance (ANOVA) for repeated measures and a Spearman rank test for correlation.
Results
Mean peripheral blood counts during IFN therapy are summarized in Table 3 . The average pretreatment Hb level of 12.9 g/dl declined to 11.9 after 6 months (P Ͻ 0.01); also mean WBC counts decreased from 9.2 × 10 9 /l to 4.3 (P Ͻ 0.001). Platelet counts were reduced from 1058 × 10 9 /l to 359 (P Ͻ 0.001) after treatment. Ten out of 11 patients met the criteria for CHR and one for PHR. Only this last patient had to be treated with 6 MU/daily for more than 1 month. Analysis of bone marrow biopsies, showed no reticulin changes at the end of the treatment. Megakaryocyte concentration was reduced in six cases. The spleen, which was enlarged in four patients, decreased in size in two patients. At the end of the IFN treatment, seven of eight patients who were symptomatic at diagnosis obtained resolution of symptoms; in one patient having acroparesthesia, symptoms persisted. 
Fourier-transform infra-red microspectroscopy
The FT-IR-M analysis was done in seven of 11 patients before and after IFN treatment in order to obtain indications about the structural modifications induced by IFN in ET Mks (Table 4) . Before treatment, we observed in all seven cases, A 1 /A 2 ratios higher than in normal controls. After IFN treatment, A 1 /A 2 ratio increased in one case, did not change in one case and decreased in five patients. In three of these patients, A 1 /A 2 ratio achieved normal values. The 95% confidence limits for the rate of reduction (five out of seven patients) in A 1 /A 2 ratio are 29-96%. Although we think the study of a higher number of ET patients might reveal a relationship, using a Spearman rank test we did not find a statistically significant correlation between the percentage reduction of the A 1 /A 2 ratio and the percentage reduction in the platelet count before and after alfa-IFN treatment (r = 0.2857). 
Clonal analysis of hematopoietic cells
All the 11 ET patients who entered the study, showed informative polymorphism for PGK and the DNA from granulocyte fraction showed clonal patterns (Table 1) . After alfa-IFN treatment we did not observe any change in the methylation patterns. The 95% confidence levels for the rate of reduction (0 out of 11 patients) for the granulocyte monoclonality are 0-30%. Granulocyte fractions obtained at the end of the treatment, were consistently clonal, while DNA from mononuclear fraction showed a polyclonal pattern. In other words, we never observed the complete disappearance of the supposedly effected clone, during hematogical remission (Figure 1 ).
Side-effects:
Mild flu-like symptoms were seen in nine out of 11 patients, especially during the first week of therapy. None of the patients showed abnormalities in liver or renal function tests. After 5 months, therapy was stopped in one CHR patient, who showed thyroiditis, which resolved only 4 months after IFN-treatment was stopped. No other patients had to discontinue alfa-IFN treatment.
Discussion
Treatment of ET patients is frequently a difficult issue. Alkylating agents and radioactive phosphorous ( 32 P) have been more or less abandoned, as they may increase the frequency of terminal blast transformation, 26 which nevertheless can occur in the natural course of the illness. 27 Hydroxyurea (HU), a nonalkylating agent, is now considered the preferred treatment in patients with ET. Although generally safe and easy to use, some authors [28] [29] [30] [31] [32] [33] have reported cases of blast transformation during HU treatment and there are also theoretical reasons to believe that this may occur. 34 Recently Cortellazzo et al 35 showed that HU is effective in preventing thrombosis in high risk patients with ET, but the same author concluded that particular care should be exercised in prescribing this drug to young patients, because the risk of secondary leukemia is not well known. Some observations 36 suggest also that pipobroman treatment may be associated with an increased incidence of terminal blast transformation. The Anagrelide Study Group has recently reported that in more than 90% of patients with thrombocytosis associated with CMD, platelet counts were reduced by at least 50% using anagrelide, but side-effects required discontinuation of treatment in 16% of cases. 37 Thus, new treatment modalities that can prevent thrombotic and hemorrhagic events and reduce the risk of acute transform- ation, are needed. This drug could be alfa-IFN, and the aim of this study is on in-depth analysis of the effect of alfa-IFN on the neoplastic clone.
Although our results were obtained in a highly selected group of patients, and therefore may not be representative of ET patients as a whole, they confirm other data (Table 5 ) and show the efficacy of alfa-IFN in ET patients: 10 out of 11 patients achieved CHR. In this study, we used FT-IR-M to obtain indications about the structural modifications induced by alfa-IFN in ET Mks. Based on previous studies 23 , 24 we have found that the A 1 /A 2 ratio increase is directly related to a proliferative impulse of the abnormal cell line, while a decrease suggests a deceleration of this proliferative impulse. The value of A 1 /A 2 ratios decreased in five of seven patients studied, showing an additional confirmation of the depth of effect of alfa-IFN on the neoplastic clone. In the CMD female patients, in which no specific genetic aberrations are known, the analy- The criteria used by authors to evaluate the hematological response vary from study to study.
sis of the X-chromosome inactivation pattern is a useful indirect approach for clonality assays. In this study, we analyzed the methylation patterns at X-linked PGK and HPRT loci to assess the clonal nature of hematopoietic reconstitution during CHR after alfa-IFN treatment, in 11 patients, in which aberrant methylation and constitutionally skewed lionization could be excluded. The determination of the clonality, before and after alfa-IFN treatment, may provide an additional approach to understand how deep the effect of this drug on the aberrant clone can be. After 6 months of treatment with alfa-IFN at a dose of 3-6 MU/day, we observed the persistence of clonal hematopoiesis in all 11 cases. Although we cannot exclude the occurrence of clonal remission in CHR ET patients, as described in acute myeloid leukemia patients, 38 we think that failure to obtain reconstitution of polyclonal hematopoiesis can be attributed to alfa-IFN dose schedules.
Restoration of a polyclonal methylation pattern was observed in CML patients after prolonged IFN treatment at a dose as high as 5 MU/m 2 /day. 20, 21 Whether higher alfa-IFN dose and/or more prolonged alfa-IFN therapy may allow a restoration of polyclonal hematopoiesis, remains to be determined and should be explored in future clinical trials. Finally, the mode of action of alfa-IFN in CMD is still not absolutely clear. We have found a decrease in megakaryocytic concentration in ET patients, 2 and a reduction in the abnormal proliferation of erythroid elements in cases of PV. 39 In both patient categories, a reduction in spleen size has also frequently been seen. With the improvement of hematological parameters, clinical symptoms have also progressed positively. We therefore believe that the sustained, unmaintained hematological remissions observed in ET patients 3, 7, 40 and the cytogenetic remission documented in PV, 41, 42 and other Ph 1 -negative CMD, 43 might be the results of a long-term tumor load reduction produced by the alfa-IFN therapy. Although we failed to show a reconstitution of polyclonal hematopoiesis, as seen in CMl patients, the decreased A 1 /A 2 ratio, at the Mk level, is a demonstration of the profound effect of alfa-IFN on the aberrant clone.
